Sangamo Therapeutics Inc Stock

$0.40+0.00 (+0%)
Updated Jul 19, 2024
SGMO Price
Fair Value Price
Market Cap
52 Week Low
52 Week High
Dividend Yield
Gross Margin
Operating Margin
Profit Margin
Debt to Equity
Operating Cash Flow
Next Earnings
Aug 6, 2024
Next Dividend

SGMO Overview

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SGMO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SGMO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SGMO is good value based on its book value relative to its share price (1.45x), compared to the US Biotechnology industry average (6.22x)
P/B vs Industry Valuation
SGMO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SGMO due diligence checks available for Premium users.

Be the first to know about important SGMO news, forecast changes, insider trades & much more!



SGMO price to earnings (PE)

For valuing profitable companies with steady earnings

SGMO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
SGMO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SGMO's financial health

Profit margin

Net Income
Profit Margin
SGMO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SGMO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Debt to equity
SGMO's short-term assets ($68.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SGMO's short-term assets ($68.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SGMO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SGMO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

SGMO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SGMO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B

Sangamo Therapeutics Stock FAQ

What is Sangamo Therapeutics's quote symbol?

(NASDAQ: SGMO) Sangamo Therapeutics trades on the NASDAQ under the ticker symbol SGMO. Sangamo Therapeutics stock quotes can also be displayed as NASDAQ: SGMO.

If you're new to stock investing, here's how to buy Sangamo Therapeutics stock.

What is the 52 week high and low for Sangamo Therapeutics (NASDAQ: SGMO)?

(NASDAQ: SGMO) Sangamo Therapeutics's 52-week high was $1.48, and its 52-week low was $0.29. It is currently -73.18% from its 52-week high and 36.43% from its 52-week low.

How much is Sangamo Therapeutics stock worth today?

(NASDAQ: SGMO) Sangamo Therapeutics currently has 207,510,076 outstanding shares. With Sangamo Therapeutics stock trading at $0.40 per share, the total value of Sangamo Therapeutics stock (market capitalization) is $82.38M.

Sangamo Therapeutics stock was originally listed at a price of $15.06 in Apr 6, 2000. If you had invested in Sangamo Therapeutics stock at $15.06, your return over the last 24 years would have been -97.36%, for an annualized return of -14.06% (not including any dividends or dividend reinvestments).

How much is Sangamo Therapeutics's stock price per share?

(NASDAQ: SGMO) Sangamo Therapeutics stock price per share is $0.40 today (as of Jul 19, 2024).

What is Sangamo Therapeutics's Market Cap?

(NASDAQ: SGMO) Sangamo Therapeutics's market cap is $82.38M, as of Jul 22, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Sangamo Therapeutics's market cap is calculated by multiplying SGMO's current stock price of $0.40 by SGMO's total outstanding shares of 207,510,076.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.